Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02373124 · ClinicalTrials.gov registry record · Phase 1
Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02373124: Completed Phase 1 study, sponsored by New York State Psychiatric Institute.
NCT02373124 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02373124, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study evaluates the feasibility of a treatment paradigm that involves naturalistic cocaine use opportunities in the context of psychotherapy aimed at utilizing these opportunities therapeutically.
Primary Outcome
Participants were provided choices to use up to 5 hits of cocaine on up to 2 occasions (cocaine versus money). Participants who chose cocaine (1 or more hits) during the first choice opportunity are administered a 52 minute infusion of 0.71 mg/kg ketamine the following day. Another choice opportunity occurs 24 hours later. The primary outcome is the choice participants made during these occasions
Interventions
- DRUG infusion of NMDA antagonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
What the finished NCT02373124 record still lists
NCT02373124 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which infusion of NMDA antagonist is the first listed.
NCT02373124 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02373124 about?
NCT02373124 is a clinical study titled "Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial". This study evaluates the feasibility of a treatment paradigm that involves naturalistic cocaine use opportunities in the context of psychotherapy aimed at utilizing these opportunities therapeutically.
What is the current status of trial NCT02373124?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2014-12. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02373124?
The interventions under investigation include: infusion of NMDA antagonist (DRUG).
Who is sponsoring clinical trial NCT02373124?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02373124's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia